Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at SAR 514.7B, ahead of Pfizer (SAR 455.4B) and Johnson & Johnson (SAR 441.5B). Figures as of 20 Nov 2026, 09:40 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieSAR 514.7B
- Median
- SAR 3.1B
- Combined market value
- SAR 14.02T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | SAR 514.7B | SAR 1.88T | SAR 1,063.81 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | SAR 455.4B | SAR 589B | SAR 103.33 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | SAR 441.5B | SAR 2.41T | SAR 1,002.28 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | SAR 322.4B | SAR 4.52T | SAR 5,069.27 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | SAR 315.9B | SAR 1.23T | SAR 498.29 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | SAR 268.4B | SAR 447.4B | SAR 218.89 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | SAR 127.3B | SAR 675B | SAR 389.71 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | SAR 84.3B | SAR 85.5B | SAR 74.59 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | SAR 45.5B | SAR 123.2B | SAR 303.12 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | SAR 37.2B | SAR 146.1B | SAR 254.08 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | SAR 34.9B | SAR 358.4B | SAR 3,464.28 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | SAR 26.2B | SAR 495.3B | SAR 1,953.46 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | SAR 25.6B | SAR 49.3B | SAR 98.64 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | SAR 15.7B | SAR 74.3B | SAR 554.61 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | SAR 13.8B | SAR 28B | SAR 80.25 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | SAR 11.6B | SAR 18.3B | SAR 218.83 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | SAR 11.4B | SAR 17B | SAR 102.13 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | SAR 11.3B | SAR 57.1B | SAR 293.32 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | SAR 7.8B | SAR 26.9B | SAR 193.07 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | SAR 5.7B | SAR 118.9B | SAR 542.00 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | SAR 5.7B | SAR 44.6B | SAR 230.44 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 3.3B | SAR 23.2B | SAR 163.77 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | SAR 2.9B | SAR 89.3B | SAR 2,097.69 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | SAR 2.7B | SAR 11.7B | SAR 60.41 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 2.5B | SAR 34.6B | SAR 1,488.53 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | SAR 2.3B | SAR 26.8B | SAR 509.06 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | SAR 2B | SAR 21.5B | SAR 1,076.57 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | SAR 2B | SAR 23.4B | SAR 358.34 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | SAR 1.8B | SAR 17.4B | SAR 181.22 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | SAR 1.6B | SAR 36.8B | SAR 243.42 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | SAR 1.1B | SAR 18.1B | SAR 104.08 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 788.5M | SAR 30.4B | SAR 438.22 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | SAR 708.5M | SAR 26.7B | SAR 243.80 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | SAR 404.4M | SAR 15.1B | SAR 110.61 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | SAR 346.4M | SAR 31.7B | SAR 39.66 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | SAR 266.3M | SAR 18.7B | SAR 53.35 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | SAR 234.7M | SAR 34.8B | SAR 366.30 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | SAR 224.3M | SAR 32.6B | SAR 1,166.47 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | SAR 200.7M | SAR 30.4B | SAR 465.31 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | SAR 140.8M | SAR 17.9B | SAR 318.27 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | SAR 113.9M | SAR 16.9B | SAR 154.47 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | SAR 62.6M | SAR 24.8B | SAR 366.07 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | SAR 37.8M | SAR 23B | SAR 566.61 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | SAR 34.4M | SAR 19.7B | SAR 466.70 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7519 SAR).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (SAR 514.7B), Pfizer (SAR 455.4B) and Johnson & Johnson (SAR 441.5B) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 09:40 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of SAR 14.02T as of 20 Nov 2026, 09:40 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.